Log in
NYSE:EBS

Emergent BioSolutions Competitors

$82.83
+2.42 (+3.01 %)
(As of 11/27/2020 12:00 AM ET)
Add
Compare
Today's Range
$80.68
Now: $82.83
$82.98
50-Day Range
$79.17
MA: $92.46
$111.47
52-Week Range
$46.37
Now: $82.83
$137.61
Volume276,544 shs
Average Volume643,144 shs
Market Capitalization$4.39 billion
P/E Ratio26.63
Dividend YieldN/A
Beta1.44

Competitors

Emergent BioSolutions (NYSE:EBS) Vs. AMGN, GILD, VRTX, REGN, BIIB, and SGEN

Should you be buying EBS stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to Emergent BioSolutions, including Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Seagen (SGEN).

Emergent BioSolutions (NYSE:EBS) and Amgen (NASDAQ:AMGN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, institutional ownership, risk and analyst recommendations.

Insider & Institutional Ownership

73.0% of Emergent BioSolutions shares are held by institutional investors. Comparatively, 71.7% of Amgen shares are held by institutional investors. 14.1% of Emergent BioSolutions shares are held by insiders. Comparatively, 0.4% of Amgen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility and Risk

Emergent BioSolutions has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500. Comparatively, Amgen has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500.

Valuation & Earnings

This table compares Emergent BioSolutions and Amgen's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Emergent BioSolutions$1.11 billion3.97$54.50 million$2.9128.46
Amgen$23.36 billion5.60$7.84 billion$14.8215.17

Amgen has higher revenue and earnings than Emergent BioSolutions. Amgen is trading at a lower price-to-earnings ratio than Emergent BioSolutions, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Emergent BioSolutions and Amgen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Emergent BioSolutions12.50%26.68%12.70%
Amgen29.42%95.55%15.52%

Analyst Ratings

This is a summary of current ratings and target prices for Emergent BioSolutions and Amgen, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Emergent BioSolutions02502.71
Amgen1121502.50

Emergent BioSolutions presently has a consensus price target of $93.1667, indicating a potential upside of 12.48%. Amgen has a consensus price target of $254.08, indicating a potential upside of 13.02%. Given Amgen's higher probable upside, analysts plainly believe Amgen is more favorable than Emergent BioSolutions.

Summary

Amgen beats Emergent BioSolutions on 9 of the 14 factors compared between the two stocks.

Emergent BioSolutions (NYSE:EBS) and Gilead Sciences (NASDAQ:GILD) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, institutional ownership, risk and analyst recommendations.

Insider & Institutional Ownership

73.0% of Emergent BioSolutions shares are held by institutional investors. Comparatively, 77.9% of Gilead Sciences shares are held by institutional investors. 14.1% of Emergent BioSolutions shares are held by insiders. Comparatively, 0.1% of Gilead Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility and Risk

Emergent BioSolutions has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500.

Valuation & Earnings

This table compares Emergent BioSolutions and Gilead Sciences' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Emergent BioSolutions$1.11 billion3.97$54.50 million$2.9128.46
Gilead Sciences$22.45 billion3.35$5.39 billion$6.149.78

Gilead Sciences has higher revenue and earnings than Emergent BioSolutions. Gilead Sciences is trading at a lower price-to-earnings ratio than Emergent BioSolutions, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Emergent BioSolutions and Gilead Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Emergent BioSolutions12.50%26.68%12.70%
Gilead Sciences5.48%37.77%12.76%

Analyst Ratings

This is a summary of current ratings and target prices for Emergent BioSolutions and Gilead Sciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Emergent BioSolutions02502.71
Gilead Sciences2151002.30

Emergent BioSolutions presently has a consensus price target of $93.1667, indicating a potential upside of 12.48%. Gilead Sciences has a consensus price target of $76.1538, indicating a potential upside of 26.86%. Given Gilead Sciences' higher probable upside, analysts plainly believe Gilead Sciences is more favorable than Emergent BioSolutions.

Summary

Gilead Sciences beats Emergent BioSolutions on 9 of the 14 factors compared between the two stocks.

Emergent BioSolutions (NYSE:EBS) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, institutional ownership, risk and analyst recommendations.

Insider & Institutional Ownership

73.0% of Emergent BioSolutions shares are held by institutional investors. Comparatively, 92.2% of Vertex Pharmaceuticals shares are held by institutional investors. 14.1% of Emergent BioSolutions shares are held by insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility and Risk

Emergent BioSolutions has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500.

Valuation & Earnings

This table compares Emergent BioSolutions and Vertex Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Emergent BioSolutions$1.11 billion3.97$54.50 million$2.9128.46
Vertex Pharmaceuticals$4.16 billion14.16$1.18 billion$4.2952.85

Vertex Pharmaceuticals has higher revenue and earnings than Emergent BioSolutions. Emergent BioSolutions is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Emergent BioSolutions and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Emergent BioSolutions12.50%26.68%12.70%
Vertex Pharmaceuticals38.51%28.55%20.68%

Analyst Ratings

This is a summary of current ratings and target prices for Emergent BioSolutions and Vertex Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Emergent BioSolutions02502.71
Vertex Pharmaceuticals082212.77

Emergent BioSolutions presently has a consensus price target of $93.1667, indicating a potential upside of 12.48%. Vertex Pharmaceuticals has a consensus price target of $290.5862, indicating a potential upside of 28.18%. Given Vertex Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Vertex Pharmaceuticals is more favorable than Emergent BioSolutions.

Summary

Vertex Pharmaceuticals beats Emergent BioSolutions on 13 of the 15 factors compared between the two stocks.

Emergent BioSolutions (NYSE:EBS) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, institutional ownership, risk and analyst recommendations.

Insider & Institutional Ownership

73.0% of Emergent BioSolutions shares are held by institutional investors. Comparatively, 85.9% of Regeneron Pharmaceuticals shares are held by institutional investors. 14.1% of Emergent BioSolutions shares are held by insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility and Risk

Emergent BioSolutions has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500.

Valuation & Earnings

This table compares Emergent BioSolutions and Regeneron Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Emergent BioSolutions$1.11 billion3.97$54.50 million$2.9128.46
Regeneron Pharmaceuticals$7.86 billion6.98$2.12 billion$21.4723.94

Regeneron Pharmaceuticals has higher revenue and earnings than Emergent BioSolutions. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Emergent BioSolutions, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Emergent BioSolutions and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Emergent BioSolutions12.50%26.68%12.70%
Regeneron Pharmaceuticals37.30%26.71%19.39%

Analyst Ratings

This is a summary of current ratings and target prices for Emergent BioSolutions and Regeneron Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Emergent BioSolutions02502.71
Regeneron Pharmaceuticals0101312.63

Emergent BioSolutions presently has a consensus price target of $93.1667, indicating a potential upside of 12.48%. Regeneron Pharmaceuticals has a consensus price target of $628.52, indicating a potential upside of 22.27%. Given Regeneron Pharmaceuticals' higher probable upside, analysts plainly believe Regeneron Pharmaceuticals is more favorable than Emergent BioSolutions.

Summary

Regeneron Pharmaceuticals beats Emergent BioSolutions on 11 of the 15 factors compared between the two stocks.

Emergent BioSolutions (NYSE:EBS) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, institutional ownership, risk and analyst recommendations.

Insider & Institutional Ownership

73.0% of Emergent BioSolutions shares are held by institutional investors. Comparatively, 78.9% of Biogen shares are held by institutional investors. 14.1% of Emergent BioSolutions shares are held by insiders. Comparatively, 0.5% of Biogen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility and Risk

Emergent BioSolutions has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.61, suggesting that its stock price is 39% less volatile than the S&P 500.

Valuation & Earnings

This table compares Emergent BioSolutions and Biogen's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Emergent BioSolutions$1.11 billion3.97$54.50 million$2.9128.46
Biogen$14.38 billion2.61$5.89 billion$33.577.26

Biogen has higher revenue and earnings than Emergent BioSolutions. Biogen is trading at a lower price-to-earnings ratio than Emergent BioSolutions, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Emergent BioSolutions and Biogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Emergent BioSolutions12.50%26.68%12.70%
Biogen35.63%51.00%23.54%

Analyst Ratings

This is a summary of current ratings and target prices for Emergent BioSolutions and Biogen, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Emergent BioSolutions02502.71
Biogen5151302.24

Emergent BioSolutions presently has a consensus price target of $93.1667, indicating a potential upside of 12.48%. Biogen has a consensus price target of $305.9032, indicating a potential upside of 25.48%. Given Biogen's higher probable upside, analysts plainly believe Biogen is more favorable than Emergent BioSolutions.

Summary

Biogen beats Emergent BioSolutions on 9 of the 14 factors compared between the two stocks.

Emergent BioSolutions (NYSE:EBS) and Seagen (NASDAQ:SGEN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, institutional ownership, risk and analyst recommendations.

Valuation & Earnings

This table compares Emergent BioSolutions and Seagen's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Emergent BioSolutions$1.11 billion3.97$54.50 million$2.9128.46
Seagen$916.71 million33.26$-158,650,000.00($1.33)-127.16

Emergent BioSolutions has higher revenue and earnings than Seagen. Seagen is trading at a lower price-to-earnings ratio than Emergent BioSolutions, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

73.0% of Emergent BioSolutions shares are held by institutional investors. Comparatively, 92.0% of Seagen shares are held by institutional investors. 14.1% of Emergent BioSolutions shares are held by insiders. Comparatively, 31.1% of Seagen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Emergent BioSolutions and Seagen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Emergent BioSolutions12.50%26.68%12.70%
Seagen-25.17%-18.32%-15.49%

Analyst Ratings

This is a summary of current ratings and target prices for Emergent BioSolutions and Seagen, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Emergent BioSolutions02502.71
Seagen161112.63

Emergent BioSolutions presently has a consensus price target of $93.1667, indicating a potential upside of 12.48%. Seagen has a consensus price target of $176.75, indicating a potential upside of 4.51%. Given Emergent BioSolutions' stronger consensus rating and higher probable upside, research analysts plainly believe Emergent BioSolutions is more favorable than Seagen.

Volatility and Risk

Emergent BioSolutions has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500. Comparatively, Seagen has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500.

Summary

Emergent BioSolutions beats Seagen on 10 of the 15 factors compared between the two stocks.


Emergent BioSolutions Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amgen logo
AMGN
Amgen
2.5$224.81+2.0%$130.88 billion$23.36 billion18.13Analyst Revision
Gilead Sciences logo
GILD
Gilead Sciences
2.9$60.03+0.9%$75.25 billion$22.45 billion61.89Analyst Revision
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.4$226.71+3.8%$58.95 billion$4.16 billion28.63
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.1$514.05+1.1%$54.85 billion$7.86 billion19.90
Biogen logo
BIIB
Biogen
2.0$243.78+0.8%$37.51 billion$14.38 billion8.07Analyst Revision
Seagen logo
SGEN
Seagen
1.4$169.12+2.2%$30.49 billion$916.71 million-112.00Analyst Downgrade
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
2.0$123.83+0.7%$27.10 billion$4.99 billion28.93
Incyte logo
INCY
Incyte
1.5$83.25+2.5%$18.23 billion$2.16 billion-53.03
Exact Sciences logo
EXAS
Exact Sciences
1.6$118.19+2.0%$17.78 billion$876.29 million-53.48
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.8$129.86+3.4%$15.09 billion$219.75 million-16.58Analyst Report
Analyst Revision
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
2.0$80.40+2.8%$14.60 billion$1.70 billion18.40
Repligen logo
RGEN
Repligen
1.4$186.99+3.0%$9.84 billion$270.24 million322.40
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$95.56+0.5%$8.93 billion$788.10 million45.29Analyst Downgrade
Novavax logo
NVAX
Novavax
1.8$125.69+18.4%$8.00 billion$18.66 million-45.71
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.8$51.13+1.7%$7.15 billion$1.12 billion106.52Insider Selling
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.2$23.24+2.1%$6.06 billion$182.24 million-20.21
United Therapeutics logo
UTHR
United Therapeutics
1.4$135.54+0.3%$6.02 billion$1.45 billion13.92
Exelixis logo
EXEL
Exelixis
1.9$19.41+3.5%$6.02 billion$967.78 million40.44Insider Selling
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$40.23+2.3%$5.44 billion$195.99 million251.44Analyst Report
Insider Selling
Analyst Revision
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$55.81+3.2%$3.86 billion$36.13 million-83.30
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$65.90+0.6%$3.83 billion$806.43 million-9.33
Alkermes logo
ALKS
Alkermes
1.3$18.50+0.4%$2.94 billion$1.17 billion-40.22
OPKO Health logo
OPK
OPKO Health
1.9$4.13+4.4%$2.77 billion$901.90 million-12.51
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.3$11.83+1.7%$1.89 billion$428.41 million17.14
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.9$119.11+6.0%$1.84 billionN/A-10.76
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.5$10.12+3.5%$1.43 billion$102.43 million-12.19
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$85.92+1.7%$1.38 billion$120.28 million-86.79
Myriad Genetics logo
MYGN
Myriad Genetics
1.3$17.78+2.4%$1.34 billion$638.60 million-6.63
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
1.9$37.27+0.3%$1.23 billion$252 million-3.60
Innoviva logo
INVA
Innoviva
1.1$10.85+2.7%$1.10 billion$261.02 million5.54
Codexis logo
CDXS
Codexis
1.1$18.01+0.8%$1.07 billion$68.46 million-51.46
ImmunoGen logo
IMGN
ImmunoGen
1.7$5.52+4.0%$1.04 billion$82.27 million-12.84Analyst Upgrade
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.6$5.13+7.2%$905.78 million$48.83 million-6.75
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.4$22.75+4.4%$900.15 million$3.57 million-10.20
MannKind logo
MNKD
MannKind
0.9$3.08+4.2%$716.41 million$63.04 million-14.67
Agenus logo
AGEN
Agenus
1.6$3.71+5.4%$705.45 million$150.05 million-3.40
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$4.73+3.6%$690.21 million$109.33 million-3.88
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.2$12.41+2.4%$678.73 million$227.19 million5.94Analyst Downgrade
Heavy News Reporting
BioSpecifics Technologies logo
BSTC
BioSpecifics Technologies
1.3$88.50+0.1%$650.03 million$38.19 million37.50
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$2.91+0.3%$623.59 million$150,000.00-4.16
Geron logo
GERN
Geron
1.4$1.87+3.2%$580.58 million$460,000.00-5.34
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$4.79+11.3%$527.73 million$35.22 million-3.50
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.11+5.8%$525.53 million$59.29 million-22.21
AMAG Pharmaceuticals logo
AMAG
AMAG Pharmaceuticals
0.8$13.75+0.0%$477.47 million$327.75 million-1.89
Molecular Templates logo
MTEM
Molecular Templates
1.6$9.12+3.1%$455.67 million$22.27 million-4.47
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$4.76+6.7%$420.40 million$143.01 million-0.91
XOMA logo
XOMA
XOMA
1.4$32.05+1.9%$353.26 million$18.37 million-28.87Analyst Report
Insider Selling
Verastem logo
VSTM
Verastem
1.5$1.99+14.6%$337.85 million$17.46 million-1.41High Trading Volume
Unusual Options Activity
Heavy News Reporting
PDL BioPharma logo
PDLI
PDL BioPharma
1.3$2.59+1.2%$295.85 million$54.76 million-1.95
Fortress Biotech logo
FBIO
Fortress Biotech
1.3$2.77+5.8%$259.56 million$36.63 million-3.18
This page was last updated on 11/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.